The RMSD values compare the latest model before a structure of the same receptor in the same state was published. Documentation
Loading...
|
ROOT-MEAN-SQUARE DEVIATION (Å)
|
RECEPTOR
|
EXPERIMENTAL STRUCTURE
|
MODEL
|
MAIN TEMPLATE
|
|||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall all |
Overall backbone |
7TM all |
7TM backbone |
H8 | ICL1 | ECL1 | ICL2 | ECL2 | ECL3 |
UniProt
|
IUPHAR | Receptor family | Cl. |
PDB
|
State | Degree active (%) |
Version | Note | GN seq. id. (%) |
GN seq. sim. (%) |
UniProt
|
IUPHAR | Receptor family | Species |
PDB
|
State | Degree active (%) |
Resolution | |
| 7.1 | 6.1 | 4.0 | 2.8 | 21.5 | 5.2 | 4.0 | 2.8 | 8.7 | 7.3 | PE2R4 | EP4 | Prostanoid | A (Rhodopsin) | 5YWY | Inactive | 17 | 2018-07-17 | TM5 modeled incorrectly due to alignment shift in TM5. The orientation of H8 is different in the structure than what was expected | 18 | 37 | 5HT2C | 5-HT2C | 5-Hydroxytryptamine | Human | 6BQH | Inactive | 1 | 2.7 | |
| 8.3 | 8.0 | 7.3 | 7.0 | 16.3 | - | 6.6 | 5.3 | 8.6 | 13.2 | TA2R | TP | Prostanoid | A (Rhodopsin) | 6IIU | Inactive | 35 | 2018-07-17 | TM5 modeled incorrectly due to alignment shift in TM5. The orientation of H8 is different in the structure than what was expected | 16 | 35 | 5HT2C | 5-HT2C | 5-Hydroxytryptamine | Human | 6BQH | Inactive | 1 | 2.7 | |
| 3.6 | 2.5 | 2.7 | 1.8 | 0.4 | 1.6 | 3.0 | 3.5 | 3.8 | - | NK1R | NK1 | Tachykinin | A (Rhodopsin) | 6HLP | Inactive | 1 | 2018-07-17 | - | 30 | 50 | OX2R | OX2 | Orexin | Human | 5WS3 | Inactive | 1 | 2.3 | |
| 3.7 | 2.9 | 3.4 | 2.5 | 4.7 | 1.1 | - | 4.6 | 3.4 | 5.9 | PTH1R | PTH1 | Parathyroid hormone | B1 (Secretin) | 6FJ3 | Inactive | 0 | 2018-07-17 | - | 42 | 60 | GLP1R | GLP-1 | Glucagon | Human | 5VEW | Inactive | 0 | 2.7 | |
| 4.4 | 3.7 | 2.7 | 2.1 | 5.5 | 2.2 | 2.9 | 1.7 | 10.4 | 5.5 | CNR2 | CB2 | Cannabinoid | A (Rhodopsin) | 5ZTY | Inactive | 6 | 2019-01-31 | - | 48 | 67 | CNR1 | CB1 | Cannabinoid | Human | 5TGZ | Inactive | 12 | 2.8 | |
| 2.9 | 2.1 | 2.3 | 1.8 | 0.7 | 0.5 | 1.7 | 6.2 | 0.9 | 5.3 | 5HT2A | 5-HT2A | 5-Hydroxytryptamine | A (Rhodopsin) | 6A94 | Inactive | 1 | 2019-01-31 | - | 70 | 83 | 5HT2C | 5-HT2C | 5-Hydroxytryptamine | Human | 6BQH | Inactive | 1 | 2.7 | |
| 5.5 | 4.4 | 3.9 | 2.6 | 5.6 | 3.0 | 7.6 | 1.6 | 9.1 | 4.9 | GPR52 | GPR52 | A orphans | A (Rhodopsin) | 6LI0 | Intermediate | 42 | 2019-03-14 | Target is closer to an intermediate activation state than inactive | 21 | 41 | 5HT2A | 5-HT2A | 5-Hydroxytryptamine | Human | 6A94 | Inactive | 1 | 2.9 | |
| 5.1 | 4.3 | 3.0 | 2.3 | 2.9 | 4.6 | 5.4 | 1.8 | 13.3 | 7.7 | MTR1B | MT2 | Melatonin | A (Rhodopsin) | 6ME6 | Inactive | 1 | 2019-03-14 | - | 24 | 47 | OX2R | OX2 | Orexin | Human | 5WS3 | Inactive | 1 | 2.3 | |
| 6.3 | 5.8 | 6.2 | 5.8 | 4.5 | 2.3 | - | 5.5 | 8.2 | 4.2 | MC4R | MC4 | Melanocortin | A (Rhodopsin) | 6W25 | Intermediate | 50 | 2019-03-14 | Target is closer to an intermediate activation state than inactive. TM5 modeled incorrectly due to alignment shift in ECL2 and TM5 | 27 | 49 | S1PR1 | S1P1 | Lysophospholipid (S1P) | Human | 3V2Y | Inactive | 1 | 2.8 | |
| 4.7 | 3.8 | 3.4 | 2.5 | 1.7 | 3.7 | 4.4 | 6.9 | 9.8 | 8.3 | MTR1A | MT1 | Melatonin | A (Rhodopsin) | 6ME2 | Inactive | 1 | 2019-03-14 | - | 25 | 49 | NPY1R | Y1 | Neuropeptide Y | Human | 5ZBH | Inactive | 0 | 3.0 | |
| 3.4 | 2.6 | 2.7 | 2.0 | 2.0 | 3.8 | 1.1 | 6.9 | 4.7 | - | CCR7 | CCR7 | Chemokine | A (Rhodopsin) | 6QZH | Inactive | 7 | 2019-03-14 | - | 39 | 62 | CCR5 | CCR5 | Chemokine | Human | 5UIW | Inactive | 25 | 2.2 | |
| 3.7 | 2.7 | 2.5 | 1.8 | 0.9 | 0.8 | 4.1 | 4.7 | 7.2 | 4.1 | ADA2C | α2C | Adrenoceptors | A (Rhodopsin) | 6KUW | Inactive | 1 | 2019-03-14 | - | 42 | 63 | DRD2 | D2 | Dopamine | Human | 6CM4 | Inactive | 0 | 2.9 | |
| 3.1 | 2.3 | 2.6 | 1.7 | 1.7 | 3.1 | 3.8 | 4.1 | 5.7 | 3.7 | ADA2A | α2A | Adrenoceptors | A (Rhodopsin) | 6KUX | Inactive | 1 | 2019-03-14 | - | 43 | 64 | DRD2 | D2 | Dopamine | Human | 6CM4 | Inactive | 0 | 2.9 | |
| 1.6 | 1.2 | 1.4 | 1.0 | 1.8 | 0.8 | 0.7 | 2.6 | 0.9 | 1.4 | ACM5 | M5 | Acetylcholine (muscarinic) | A (Rhodopsin) | 6OL9 | Inactive | 4 | 2019-03-14 | - | 80 | 93 | ACM3 | M3 | Acetylcholine (muscarinic) | Rat | 4U15 | Inactive | 4 | 2.8 | |
| 3.4 | 2.4 | 3.0 | 1.9 | 2.1 | 0.8 | 3.0 | 4.2 | 3.8 | - | CXCR2 | CXCR2 | Chemokine | A (Rhodopsin) | 6LFL | Inactive | 7 | 2019-09-02 | - | 41 | 63 | CCR7 | CCR7 | Chemokine | Human | 6QZH | Inactive | 7 | 2.1 | |
| 7.0 | 6.3 | 3.2 | 2.4 | - | 4.8 | 6.6 | 9.5 | 15.3 | 2.6 | GABR2 | GABAB2 | GABAB | C (Glutamate) | 6VJM | Inactive | 6 | 2020-07-30 | - | 20 | 40 | GRM5 | mGlu5 | Metabotropic glutamate | Human | 4OO9 | Inactive | 15 | 2.6 | |
| 5.5 | 4.9 | 2.8 | 2.0 | - | 1.3 | 11.1 | - | 10.1 | 5.4 | GABR1 | GABAB1 | GABAB | C (Glutamate) | 6W2Y | Inactive | 0 | 2020-07-30 | - | 19 | 40 | GRM5 | mGlu5 | Metabotropic glutamate | Human | 4OO9 | Inactive | 15 | 2.6 | |
| 3.5 | 2.5 | 3.0 | 2.3 | - | - | 3.0 | 2.8 | 3.4 | 3.1 | OXYR | OT | Vasopressin and oxytocin | A (Rhodopsin) | 6TPK | Active | 79 | 2020-07-30 | - | 19 | 39 | NK1R | NK1 | Tachykinin | Human | 6HLP | Inactive | 1 | 2.2 | |
| 3.9 | 2.7 | 3.1 | 2.1 | 2.1 | 4.7 | 2.9 | 4.0 | 3.3 | - | GHSR | ghrelin | Ghrelin | A (Rhodopsin) | 6KO5 | Inactive | 1 | 2020-07-30 | - | 35 | 53 | NTR1 | NTS1 | Neurotensin | Rat | 4BUO | Inactive | 3 | 2.8 | |
| 4.6 | 4.4 | 3.0 | 2.3 | - | - | 5.7 | - | 8.8 | 4.5 | GNRHR | GnRH1 | Gonadotrophin-releasing hormone | A (Rhodopsin) | 7BR3 | Active | 79 | 2020-09-02 | - | 27 | 50 | OXYR | OT | Vasopressin and oxytocin | Human | 6TPK | Active | 79 | 3.2 | |
| 5.7 | 4.9 | 2.4 | 1.4 | 2.3 | 2.4 | 17.4 | 1.5 | 1.1 | - | FZD5 | FZD5 | Frizzled | F (Frizzled) | 6WW2 | Inactive | 17 | 2020-09-02 | GPCRdb ECL1 was modeled freely without a template | 58 | 75 | FZD4 | FZD4 | Frizzled | Human | 6BD4 | Inactive | 17 | 2.4 | |